Neuropsychological practice effects and change detection in people with schizophrenia

Beglinger, Leigh J.; Ahmed, Sarah; Derby, Michael A.; Siemers, Eric; Fastenau, Philip S.; Crawford-Miller, J.; Shekhar, Anantha; Kareken, David A.

doi:10.1016/s0920-9964(02)00425-5

Cited by 18 publications

(13 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…36,37 Nevertheless, practice effects based upon procedural learning, (i.e., improved performance due to increasing familiarity with the test rules), cannot be excluded, particularly in this cohort of generally well-educated patients with high levels of occupational functioning. 38,39 Future longitudinal studies of cognitive function in chronic hepatitis C patients should incorporate tests with multiple alternate forms as well as a control group of patients not receiving antiviral therapy to minimize any potential procedural learning or practice effects.…”

Section: Discussionmentioning

confidence: 99%

Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C†‡

et al. 2007

View full text Add to dashboard Cite

Treatment of chronic hepatitis C with pegylated interferon (peginterferon) and ribavirin can cause or exacerbate depression but its effects on cognitive function are largely unknown. The aim of this study was to determine whether treatment with peginterferon and ribavirin adversely impacts cognitive function in patients with chronic hepatitis C. Prior nonresponders to interferon were retreated with peginterferon alfa-2a and ribavirin for 24 (n ‫؍‬ 177) or 48 weeks (n ‫؍‬ 57) in the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial. Cognitive function was prospectively assessed using a battery of 10 standardized neuropsychological tests at weeks 0, 24, 48, and 72. Cognitive impairment was defined based upon a global deficit score. The Beck Depression Inventory and Brief Symptom Inventory were used to assess mood status. The 57 subjects who completed 48 weeks of antiviral therapy reported significant increases in difficulty concentrating, emotional distress, and symptoms of depression, all of which improved after cessation of therapy [P < 0.0001, analysis of variance (ANOVA)]. Nonetheless, the frequency of cognitive impairment did not increase during the first 24 weeks of treatment in 177 patients (34% versus 32%, P ‫؍‬ 0.64) nor in the 57 patients completing 48 weeks of treatment (P ‫؍‬ 0.48, ANOVA). Conclusion: Retreatment of prior non-responders with peginterferon and ribavirin was not associated with objective evidence of cognitive impairment as measured by a comprehensive battery of neuropsychological tests. The lack of cognitive impairment is reassuring and suggests that self-reported symptoms of cognitive dysfunction are more likely related to the systemic and psychiatric side effects of antiviral treatment rather than measurable changes in cognition.

show abstract

Section: Discussionmentioning

confidence: 99%

Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C†‡

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Findings from the initial validation study suggested the Bell-Lysaker Emotion Recognition Task ( BLERT ; Bell, Bryson, & Lysaker, 1997), Penn Emotion Recognition Task ( ER-40 ; Kohler et al, 2003), Reading the Mind in the Eyes Test ( Eyes ; Baron-Cohen et al, 2003), The Awareness of Social Inferences Test ( TASIT ; McDonald et al, 2003), and Hinting Task ( Hinting ; Corcoran, Mercer, & Frith, 1995), displayed acceptable reliability and validity for implementation in clinical research. Remaining measures, including: Ambiguous Intentions Hostility Questionnaire ( AIHQ ; Combs et al, 2007), Relationships Across Domains ( RAD ; Sergi et al, 2009), and Trustworthiness Task ( Trust ; Adolphs, Tranel, & Damasio, 1998), demonstrated weaker characteristics and were deemed inadequate for use in clinical trials targeting social cognition (Pinkham et al, 2015), although subsequent findings support continued development and use of the AIHQ Blame Score (Buck et al, 2017, in press).…”

Section: Introductionmentioning

confidence: 99%

Social cognition psychometric evaluation (SCOPE) in people with early psychosis: A preliminary study

Ludwig

Pinkham

Harvey

et al. 2017

Schizophrenia Research

View full text Add to dashboard Cite

Social cognition is an important outcome in schizophrenia research. Unfortunately, there has been a lack of consensus regarding which measures of social cognition best capture this domain of functioning. The Social Cognition Psychometric Evaluation (SCOPE) study was developed to address the need for a battery of measures that have sound psychometric properties and can be implemented in clinical trials for individuals with chronic schizophrenia. The current study expands upon the SCOPE study by examining the psychometric properties of the eight candidate measures administered to individuals early in the course of psychosis. Thirty-eight stable outpatients with first episode psychosis and thirty-nine healthy controls completed the battery at baseline and one-month follow-up assessments. The SCOPE battery was evaluated on a collection of psychometric properties, including: (1) Reliability – including test-retest and internal consistency, (2) Between group differences, (3) Utility as a repeated measure, (4) Relationship to social and occupational functioning, (5) Incremental validity – variance in functioning beyond neurocognition, and (6) Feasibility – including practicality of administration and tolerability. Social cognition accounted for substantially more variance in functional outcome than neurocognition. Only one measure, the Hinting task, displayed adequate psychometric properties to be recommended for use in clinical research with first episode psychosis. The remaining candidate measures would require modifications before implementation or cannot be recommended for use in clinical research with first episode psychosis.

show abstract

“…Longitudinal studies generally show that cognitive deficits are stable over long periods in chronic schizophrenia although there is evidence for decline in elderly institutionalised patients [4-6]. However these studies demonstrating cognitive stability usually involve a baseline assessment and a single follow-up [7,8], so would not detect any shorter-term fluctuations in cognitive performance [9]. For example, cognitive function might fluctuate alongside day-to-day changes in symptom levels or, less dramatically, might be relatively improved during remitted phases and relatively worse during relapse.…”

Section: Introductionmentioning

confidence: 99%

Improvement and decline of cognitive function in schizophrenia over one year: a longitudinal investigation using latent growth modelling

et al. 2007

View full text Add to dashboard Cite

show abstract

Neuropsychological practice effects and change detection in people with schizophrenia

Cited by 18 publications

References 6 publications

Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C†‡

Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C†‡

Social cognition psychometric evaluation (SCOPE) in people with early psychosis: A preliminary study

Improvement and decline of cognitive function in schizophrenia over one year: a longitudinal investigation using latent growth modelling

Contact Info

Product

Resources

About